Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro
- PMID: 38512650
- DOI: 10.1007/s11418-024-01788-0
Inhibitory effects of senkyuchachosan on SARS-CoV-2 papain-like protease activity in vitro
Abstract
Papain-like protease (PLpro) enzyme plays a vital role in viral replication as it breaks down polyproteins and disrupts the host's immune response. There are few reports on Kampo formulas that focus on PLpro activity. In this study, we evaluated the inhibitory effects of senkyuchachosan, a traditional Japanese medicine, on PLpro of SARS-CoV-2, the virus responsible for causing COVID-19. We purified the PLpro enzyme and conducted in vitro enzymatic assays using specific substrates. Among the nine crude drugs present in senkyuchachosan, four (Cyperi Rhizoma, Schizonepetae Spica, Menthae Herba, and Camelliae sinensis Folium [CsF]) strongly inhibited PLpro activity. CsF, derived from Camellia sinensis (green tea), contains polyphenols, including catechins and tannins. To confirm that the PLpro inhibitory effects of senkyuchachosan predominantly stem from tannins, the tannins were removed from the decoction using polyvinylpolypyrrolidone (PVPP). The inhibitory effect of senkyuchachosan on PLpro activity was reduced by the removal of PVPP. In addition, the tannin fraction obtained from the CsF extracts showed significant PLpro inhibitory effects. These findings lay the groundwork for the potential development of therapeutic agents that target SARS-CoV-2 infection by intervening in proteolytic cleavage of the virus.
Keywords: Catechin; Kampo; Papain-like protease; SARS-CoV-2; Senkyuchachosan.
© 2024. The Author(s) under exclusive licence to The Japanese Society of Pharmacognosy.
Similar articles
-
Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.Biol Pharm Bull. 2024;47(5):965-966. doi: 10.1248/bpb.b24-00038. Biol Pharm Bull. 2024. PMID: 38763750
-
Characterization of the Trans-Epithelial Transport of Green Tea (C. sinensis) Catechin Extracts with In Vitro Inhibitory Effect against the SARS-CoV-2 Papain-like Protease Activity.Molecules. 2021 Nov 8;26(21):6744. doi: 10.3390/molecules26216744. Molecules. 2021. PMID: 34771162 Free PMC article.
-
Discovery of SARS-CoV-2 papain-like protease inhibitors through machine learning and molecular simulation approaches.Drug Discov Ther. 2025 Jul 4;19(3):189-199. doi: 10.5582/ddt.2025.01034. Epub 2025 Jun 27. Drug Discov Ther. 2025. PMID: 40571587
-
Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme.Molecules. 2025 Jan 23;30(3):491. doi: 10.3390/molecules30030491. Molecules. 2025. PMID: 39942596 Free PMC article. Review.
-
Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.Eur J Med Chem. 2022 Oct 5;240:114572. doi: 10.1016/j.ejmech.2022.114572. Epub 2022 Jul 3. Eur J Med Chem. 2022. PMID: 35797899 Free PMC article. Review.
References
-
- Kumar A, Singh R, Kaur J, et al Wuhan to World: The COVID-19 Pandemic. https://doi.org/10.3389/fcimb.2021.596201
-
- Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019 . Accessed 27 Jul 2023
-
- Sarangi MK, Padhi S, Dheeman S et al (2022) Diagnosis, prevention, and treatment of coronavirus disease: a review. Expert Rev Anti Infect Ther 20:243–266. https://doi.org/10.1080/14787210.2021.1944103 - DOI - PubMed
-
- Gordon DE, Jang GM, Bouhaddou M et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459–468. https://doi.org/10.1038/S41586-020-2286-9 - DOI - PubMed - PMC
-
- Freitas BT, Durie IA, Murray J et al (2020) Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease. ACS Infect Dis 6:2099–2109. https://doi.org/10.1021/ACSINFECDIS.0C00168 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous